Vabysmo

(Faricimab-svoa)

Vabysmo

Drug updated on 11/16/2023

Dosage FormInjection (intravitreal; 120 mg/Ml)
Drug ClassMultiple
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
  • For the treatment of patients with Diabetic Macular Edema (DME).
  • For the treatment of patients with Macular Edema Following Retinal Vein Occlusion (RVO)